April 19, 2018 12:22 PM ET


Company Overview of MOTUS THERAPEUTICS, INC.

Company Overview

MOTUS THERAPEUTICS, INC., a biopharmaceutical company, develops peptide therapeutics for the treatment of gastrointestinal (GI) diseases. The company’s product candidate, relamorelin, is a potent, ghrelin peptide agonist for the treatment of diabetic gastroparesis, a GI complication of diabetes, and other GI functional disorders. Its relamorelin is derived from the natural ghrelin sequence that targets the receptor for ghrelin, which is a naturally occurring hormone that plays a critical role in GI motility, digestion, and the absorption of nutrients. MOTUS THERAPEUTICS, INC. was formerly known as Rhythm Pharmaceuticals, Inc. and changed its name to MOTUS THERAPEUTICS, INC. in September 2014...

855 Boylston Street

11th Floor

Boston, MA 02116

United States

Founded in 2008






Chief Executive Officer and Director
Age: 63
Founder and President
Age: 58
Founder and Member of Scientific Advisory Board
Age: 67
Chief Medical Officer
Age: 62
Chief Scientific Officer
Age: 62
Compensation as of Fiscal Year 2017.


Rhythm Names Hunter Smith as New Chief Financial Officer

Rhythm named Hunter Smith as its new chief financial officer effective immediately. Smith has more than 20 years of global finance and management experience across multiple industries and financial disciplines, including expertise in business analysis and planning, mergers and acquisitions, capital raising and investor relations. He joins the company from Celgene Corporation, where he served as vice president, Finance and chief financial officer of the company's Inflammation and Immunology Business Unit.

Rhythm Pharmaceuticals Inc. Announces Expansion of Phase Ii Obesity Trial

Rhythm Pharmaceuticals Inc. announced the expansion of its Phase II clinical trials of setmelanotide to the treatment of Bardet Biedl syndrome (BBS) obesity. Setmelanotide is a potent, first-in-class melanocortin-4 receptor (MC4R) agonist in development for the treatment of obesity caused by genetic deficiencies in the MC4 pathway, a key biological pathway in humans that regulates weight by increasing energy expenditure and reducing appetite. This initial study is an open-label, Phase II clinical trial of setmelanotide for the treatment of BBS obesity. The clinical trial will evaluate the safety and efficacy of setmelanotide administered once daily by subcutaneous injection in patients with BBS obesity. Setmelanotide is a potent, first-in-class MC4R agonist in development for the treatment of obesity caused by genetic deficiencies in the MC4 pathway, a key biological pathway in humans that regulates weight by increasing energy expenditure and reducing appetite. The critical role of the MC4 pathway in weight regulation was validated with the discovery that single genetic defects along this pathway result in early-onset and severe obesity.

Rhythm Pharmaceuticals Names David Meeker as Chairman

Rhythm Pharmaceuticals has appointed David Meeker as chairman of the board. Currently, Meeker serves at Genzyme as its president and chief executive officer.

Similar Private Companies By Industry

Company Name Region
1st Order Pharmaceuticals, Inc. United States
21st Century Animal Health United States
3 Buds' Organics LLC United States
4P Therapeutics LLC United States
60° Pharmaceuticals, LLC United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
The Advertising Council, Inc. United States
Tax Management Inc United States
John F. Kennedy Center For The Performing Arts United States
NYC2012, Inc. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact MOTUS THERAPEUTICS, INC., please visit www.motustx.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.